Literature DB >> 33223085

Advances in the Treatment of Multiple Sclerosis.

Carolyn Goldschmidt1, Marisa P McGinley2.   

Abstract

Multiple sclerosis is a relatively common, immune-mediated neurologic disease of the central nervous system that can cause significant disability and lead to reduced quality of life. There are several currently approved disease-modifying therapies, and more in the pipeline being developed and tested. As the field learns more about the pathophysiology and natural course of the disease, the treatment approaches are also being investigated. This article reviews data on available treatments along with a discussion of future treatment targets under investigation.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease-modifying treatment; Multiple sclerosis; Neuroprotection therapies; Remyelination therapies; Treatment approaches

Mesh：

Substances：

Year:  2020        PMID： 33223085      PMCID： PMC7687744          DOI： 10.1016/j.ncl.2020.09.002

Source DB:  PubMed          Journal:  Neurol Clin        ISSN： 0733-8619            Impact factor:   3.806


  51 in total

Review 1.  Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.

Authors:  Daniel Ontaneda; Emma Tallantyre; Tomas Kalincik; Sarah M Planchon; Nikos Evangelou
Journal:  Lancet Neurol       Date:  2019-07-30       Impact factor: 44.182

2.  Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Authors:  Ludwig Kappos; Amit Bar-Or; Bruce A C Cree; Robert J Fox; Gavin Giovannoni; Ralf Gold; Patrick Vermersch; Douglas L Arnold; Sophie Arnould; Tatiana Scherz; Christian Wolf; Erik Wallström; Frank Dahlke
Journal:  Lancet       Date:  2018-03-23       Impact factor: 79.321

3.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Authors:  Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

4.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Authors:  Gavin Giovannoni; Giancarlo Comi; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Peter Chang; Anthony Hamlett; Bruno Musch; Steven J Greenberg
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

5.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

6.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Authors:  Jeffrey A Cohen; Giancarlo Comi; Krzysztof W Selmaj; Amit Bar-Or; Douglas L Arnold; Lawrence Steinman; Hans-Peter Hartung; Xavier Montalban; Eva Kubala Havrdová; Bruce A C Cree; James K Sheffield; Neil Minton; Kartik Raghupathi; Vivian Huang; Ludwig Kappos
Journal:  Lancet Neurol       Date:  2019-09-03       Impact factor: 44.182

Review 7.  NEDA treatment target? No evident disease activity as an actionable outcome in practice.

Authors:  Natalie E Parks; Eoin P Flanagan; Claudia F Lucchinetti; Dean M Wingerchuk
Journal:  J Neurol Sci       Date:  2017-10-13       Impact factor: 3.181

8.  Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

Authors:  Rebecca Spain; Katherine Powers; Charles Murchison; Elizabeth Heriza; Kimberly Winges; Vijayshree Yadav; Michelle Cameron; Ed Kim; Fay Horak; Jack Simon; Dennis Bourdette
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-06-28

Review 9.  Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management.

Authors:  David J Epstein; Jeffrey Dunn; Stan Deresinski
Journal:  Open Forum Infect Dis       Date:  2018-07-16       Impact factor: 3.835

10.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910
View more
  10 in total

1.  Therapeutic Potential of Combined Therapy of Vitamin A and Vitamin C in the Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats.

Authors:  Mojdeh Navidhamidi; Atena Nazari; Samaneh Dehghan; Anahita Ebrahimpour; Reza Nasrnezhad; Fereshteh Pourabdolhossein
Journal:  Mol Neurobiol       Date:  2022-01-24       Impact factor: 5.590

2.  The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis.

Authors:  Devi Sai Sri Kavya Boorgu; Shruthi Venkatesh; Chirag M Lakhani; Elizabeth Walker; Ines M Aguerre; Claire Riley; Chirag J Patel; Philip L De Jager; Zongqi Xia
Journal:  Mult Scler Relat Disord       Date:  2022-06-24       Impact factor: 4.808

3.  Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE.

Authors:  Thomas O Schrader; Yifeng Xiong; Ariana O Lorenzana; Alexander Broadhead; Karin J Stebbins; Michael M Poon; Christopher Baccei; Daniel S Lorrain
Journal:  ACS Med Chem Lett       Date:  2020-12-24       Impact factor: 4.345

4.  Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology.

Authors:  José I Fernández-Velasco; Enric Monreal; Jens Kuhle; Virginia Meca-Lallana; José Meca-Lallana; Guillermo Izquierdo; Celia Oreja-Guevara; Francisco Gascón-Giménez; Susana Sainz de la Maza; Paulette E Walo-Delgado; Paloma Lapuente-Suanzes; Aleksandra Maceski; Eulalia Rodríguez-Martín; Ernesto Roldán; Noelia Villarrubia; Albert Saiz; Yolanda Blanco; Carolina Diaz-Pérez; Gabriel Valero-López; Judit Diaz-Diaz; Yolanda Aladro; Luis Brieva; Cristina Íñiguez; Inés González-Suárez; Luis A Rodríguez de Antonio; José M García-Domínguez; Julia Sabin; Sara Llufriu; Jaime Masjuan; Lucienne Costa-Frossard; Luisa M Villar
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

5.  Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis.

Authors:  Michael Platten; Russell Ouellette; Elena Herranz; Valeria Barletta; Constantina A Treaba; Caterina Mainero; Tobias Granberg
Journal:  J Neuroimaging       Date:  2022-02-14       Impact factor: 2.324

6.  Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.

Authors:  Massimo Filippi; Maria Pia Amato; Diego Centonze; Paolo Gallo; Claudio Gasperini; Matilde Inglese; Francesco Patti; Carlo Pozzilli; Paolo Preziosa; Maria Trojano
Journal:  J Neurol       Date:  2022-05-24       Impact factor: 6.682

7.  The Design, Development, and Testing of a Virtual Reality Device for Upper Limb Training in People With Multiple Sclerosis: Single-Center Feasibility Study.

Authors:  Alon Kalron; Lior Frid; Iliya Fonkatz; Shay Menascu; Mark Dolev; David Magalashvili; Anat Achiron
Journal:  JMIR Serious Games       Date:  2022-09-12       Impact factor: 3.364

8.  Piperine Improves Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats Through its Neuroprotective, Anti-inflammatory, and Antioxidant Effects.

Authors:  Reza Nasrnezhad; Sohrab Halalkhor; Farzin Sadeghi; Fereshteh Pourabdolhossein
Journal:  Mol Neurobiol       Date:  2021-08-02       Impact factor: 5.590

9.  Molecular Examination of Differentially Expressed Genes in the Brains of Experimental Autoimmune Encephalomyelitis Mice Post Herceptin Treatment.

Authors:  Mena Al-Ani; Noha Mousaad Elemam; Ibrahim Y Hachim; Tom K Raju; Jibran Sualeh Muhammad; Mahmood Y Hachim; Riyad Bendardaf; Azzam A Maghazachi
Journal:  J Inflamm Res       Date:  2021-06-17

10.  Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation.

Authors:  S K Vainio; A M Dickens; M Matilainen; F R López-Picón; R Aarnio; O Eskola; O Solin; D C Anthony; J O Rinne; L Airas; M Haaparanta-Solin
Journal:  EJNMMI Res       Date:  2022-02-02       Impact factor: 3.138
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.